Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs61222160

Full Text :

https://doi.org/10.1182/blood-2022-167581